Abbisko Cayman (STU:8ZD) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Abbisko Cayman Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Abbisko Cayman's annualized Gross Profit for the quarter that ended in Dec. 2023 was €0.00 Mil. Abbisko Cayman's average Total Assets over the quarter that ended in Dec. 2023 was €287.14 Mil. Therefore, Abbisko Cayman's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.

Abbisko Cayman Gross-Profit-to-Asset % Historical Data

The historical data trend for Abbisko Cayman's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman Gross-Profit-to-Asset % Chart

Abbisko Cayman Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

1.39

0.80

Abbisko Cayman Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial			1.71	-	-	1.54	-

Competitive Comparison of Abbisko Cayman's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Abbisko Cayman's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abbisko Cayman's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abbisko Cayman's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Abbisko Cayman's Gross-Profit-to-Asset % falls into.

Abbisko Cayman Gross-Profit-to-Asset % Calculation

Abbisko Cayman's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	2.448	/	( (337.096	+	271.674)	/ 2 )
	=	2.448	/	304.385
	=	0.80 %

Abbisko Cayman's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0	/	( (302.601	+	271.674)	/ 2 )
	=	0	/	287.1375
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Abbisko Cayman Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Abbisko Cayman (STU:8ZD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (STU:8ZD) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

02256:Hong Kong

Address

Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN

Website

https://www.abbisko.com

Abbisko Cayman Ltd is a investment holding company it operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.

Abbisko Cayman (STU:8ZD) Headlines

No Headlines